Shattuck reports 79% ORR in frontline HR-MDS and 27% CR/CRi in TP53m AML from SL-172154 trial

Shattuck Labs, Inc.

79% objective response rate (ORR) with 64% complete response (CR)/marrow CR in 14 evaluable frontline HR-MDS patients.
27% initial CR/CRi in 11 evaluable frontline TP53m AML patients; 5 achieved stable disease with decreasing blasts.
SL-172154 + azacitidine showed acceptable safety; no destructive anemia; most common TEAE was infusion-related reaction.
Cohorts expanding; Shattuck expects next data update by mid-2024.
Monotherapy response in R/R AML patient allowed stem cell transplant; patient remains disease-free.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.